Aviko Radiopharmaceuticals

Executive Summary

Aviko Radiopharmaceuticals is a privately held biotech company pioneering boron-based radiopharmaceuticals for Boron Neutron Capture Therapy (BNCT), a precision oncology modality that selectively destroys solid tumors. Founded in 2019 and headquartered in Houston, Texas, the company aims to overcome key limitations of conventional BNCT by developing novel boron delivery agents with improved tumor selectivity and pharmacokinetics. Aviko's approach leverages proprietary boron chemistry to enhance neutron capture efficiency, potentially expanding BNCT's applicability to a wider range of cancers, including those resistant to standard therapies. By building an ecosystem of partnerships with drug developers and medical centers, Aviko seeks to integrate its radiopharmaceuticals into existing clinical workflows, accelerating adoption of this targeted therapy. The radiopharmaceutical market is growing rapidly, driven by demand for theranostic agents and targeted radionuclide therapies. Aviko's focus on BNCT—a modality with a long history but limited deployment due to technical challenges—positions it at the forefront of a resurgence fueled by advances in accelerator-based neutron sources and boron delivery. While still in early development, the company's technology could address significant unmet needs in head and neck cancers, glioblastoma, and other deep-seated tumors. However, as a private company with no disclosed funding or clinical data, execution risk remains high. Aviko's success hinges on advancing its lead candidate into clinical trials and securing collaborative partnerships to validate its platform.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for Lead BNCT Candidate40% success
• Q2 2026Partnership with a Major Cancer Center for BNCT Infrastructure60% success
• Q3 2026Preclinical Data Presentation at SNMMI Annual Meeting75% success